3 Stocks Underperforming Today In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,435 as of Friday, May 16, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,512 issues advancing vs. 1,401 declining with 184 unchanged.

The Health Care sector currently sits down 0.8% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include NPS Pharmaceuticals ( NPSP), down 5.0%, InterMune ( ITMN), down 5.0%, Isis Pharmaceuticals ( ISIS), down 4.8%, Incyte ( INCY), down 4.6% and Seattle Genetics ( SGEN), down 4.2%. Top gainers within the sector include Intuitive Surgical ( ISRG), up 1.8%, Regeneron Pharmaceuticals ( REGN), up 1.4%, CR Bard ( BCR), up 1.1%, Agilent Technologies ( A), up 1.0% and Thermo Fisher Scientific ( TMO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Illumina ( ILMN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Illumina is down $2.60 (-1.8%) to $142.15 on light volume. Thus far, 502,244 shares of Illumina exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $140.60-$146.00 after having opened the day at $145.74 as compared to the previous trading day's close of $144.75.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $18.6 billion and is part of the drugs industry. Shares are up 30.9% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.30 (-0.6%) to $49.48 on light volume. Thus far, 1.9 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.9 million shares. The stock has ranged in price between $49.28-$50.00 after having opened the day at $49.53 as compared to the previous trading day's close of $49.78.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $43.0 billion and is part of the drugs industry. Shares are up 24.9% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Biogen Idec ( BIIB) is down $1.69 (-0.6%) to $287.84 on average volume. Thus far, 671,720 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $285.01-$291.68 after having opened the day at $288.49 as compared to the previous trading day's close of $289.53.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $70.3 billion and is part of the drugs industry. Shares are up 3.6% year-to-date as of the close of trading on Thursday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Stocks Rise, Nasdaq Jumps as Facebook Rallies

Stocks Rise, Nasdaq Jumps as Facebook Rallies

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Earnings, Earnings and More Earnings - Your Midweek Update From Facebook to Ford

Earnings, Earnings and More Earnings - Your Midweek Update From Facebook to Ford

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk